vs
PERDOCEO EDUCATION Corp（PRDO）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
PERDOCEO EDUCATION Corp的季度营收约是再鼎医药的1.7倍（$211.6M vs $127.1M），PERDOCEO EDUCATION Corp同比增速更快（20.0% vs 17.1%），PERDOCEO EDUCATION Corp自由现金流更多（$37.9M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 12.2%）
Perdoceo Education是美国上市营利性教育集团，前身为职业教育公司（Career Education Corporation），旗下运营五所美国营利性大学，包括美国洲际大学、科罗拉多理工大学、南加利福尼亚大学、三叉戟国际大学及圣奥古斯丁健康科学大学，业务覆盖高等教育、职业教育及健康科学相关教育领域。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
PRDO vs ZLAB — 直观对比
营收规模更大
PRDO
是对方的1.7倍
$127.1M
营收增速更快
PRDO
高出2.8%
17.1%
自由现金流更多
PRDO
多$64.6M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
12.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $211.6M | $127.1M |
| 净利润 | — | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 19.8% | -54.6% |
| 净利率 | — | — |
| 营收同比 | 20.0% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.55 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRDOZLAB
| Q4 25 | $211.6M | $127.1M | ||
| Q3 25 | $211.9M | $115.4M | ||
| Q2 25 | $209.6M | $109.1M | ||
| Q1 25 | $213.0M | $105.7M | ||
| Q4 24 | $176.4M | $108.5M | ||
| Q3 24 | $169.8M | $101.8M | ||
| Q2 24 | $166.7M | $100.1M | ||
| Q1 24 | $168.3M | $87.1M |
净利润PRDOZLAB
| Q4 25 | — | — | ||
| Q3 25 | $39.9M | $-36.0M | ||
| Q2 25 | $41.0M | $-40.7M | ||
| Q1 25 | $43.7M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $38.3M | $-41.7M | ||
| Q2 24 | $38.4M | $-80.3M | ||
| Q1 24 | $39.4M | $-53.5M |
毛利率PRDOZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率PRDOZLAB
| Q4 25 | 19.8% | -54.6% | ||
| Q3 25 | 24.1% | -42.3% | ||
| Q2 25 | 24.5% | -50.3% | ||
| Q1 25 | 24.3% | -53.3% | ||
| Q4 24 | 21.1% | -62.6% | ||
| Q3 24 | 26.4% | -66.6% | ||
| Q2 24 | 27.6% | -76.0% | ||
| Q1 24 | 27.5% | -80.7% |
净利率PRDOZLAB
| Q4 25 | — | — | ||
| Q3 25 | 18.8% | -31.2% | ||
| Q2 25 | 19.6% | -37.3% | ||
| Q1 25 | 20.5% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | 22.5% | -40.9% | ||
| Q2 24 | 23.0% | -80.2% | ||
| Q1 24 | 23.4% | -61.4% |
每股收益（稀释后）PRDOZLAB
| Q4 25 | $0.55 | $-0.05 | ||
| Q3 25 | $0.60 | $-0.03 | ||
| Q2 25 | $0.62 | $-0.04 | ||
| Q1 25 | $0.65 | $-0.04 | ||
| Q4 24 | $0.46 | $-0.09 | ||
| Q3 24 | $0.57 | $-0.04 | ||
| Q2 24 | $0.57 | $-0.08 | ||
| Q1 24 | $0.59 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $111.0M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $972.4M | $715.5M |
| 总资产 | $1.2B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PRDOZLAB
| Q4 25 | $111.0M | $689.6M | ||
| Q3 25 | $159.5M | $717.2M | ||
| Q2 25 | $172.1M | $732.2M | ||
| Q1 25 | $132.1M | $757.3M | ||
| Q4 24 | $109.1M | $779.7M | ||
| Q3 24 | $238.0M | $616.1M | ||
| Q2 24 | $127.9M | $630.0M | ||
| Q1 24 | $125.8M | $650.8M |
股东权益PRDOZLAB
| Q4 25 | $972.4M | $715.5M | ||
| Q3 25 | $997.9M | $759.9M | ||
| Q2 25 | $984.6M | $791.7M | ||
| Q1 25 | $970.3M | $810.8M | ||
| Q4 24 | $959.5M | $840.9M | ||
| Q3 24 | $935.4M | $667.7M | ||
| Q2 24 | $899.5M | $704.2M | ||
| Q1 24 | $866.1M | $762.2M |
总资产PRDOZLAB
| Q4 25 | $1.2B | $1.2B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.3B | $1.2B | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | $1.1B | $985.3M | ||
| Q2 24 | $1.1B | $987.4M | ||
| Q1 24 | $1.1B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $40.1M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $37.9M | $-26.7M |
| 自由现金流率自由现金流/营收 | 17.9% | -21.0% |
| 资本支出强度资本支出/营收 | 1.1% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $216.7M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流PRDOZLAB
| Q4 25 | $40.1M | $-26.0M | ||
| Q3 25 | $41.2M | $-32.0M | ||
| Q2 25 | $78.8M | $-31.0M | ||
| Q1 25 | $65.1M | $-61.7M | ||
| Q4 24 | $17.6M | $-55.8M | ||
| Q3 24 | $51.0M | $-26.8M | ||
| Q2 24 | $38.5M | $-42.2M | ||
| Q1 24 | $54.5M | $-90.1M |
自由现金流PRDOZLAB
| Q4 25 | $37.9M | $-26.7M | ||
| Q3 25 | $39.4M | $-35.0M | ||
| Q2 25 | $76.0M | $-33.9M | ||
| Q1 25 | $63.4M | $-63.2M | ||
| Q4 24 | $16.0M | $-58.4M | ||
| Q3 24 | $50.0M | $-28.2M | ||
| Q2 24 | $37.7M | $-42.9M | ||
| Q1 24 | $53.3M | $-91.1M |
自由现金流率PRDOZLAB
| Q4 25 | 17.9% | -21.0% | ||
| Q3 25 | 18.6% | -30.4% | ||
| Q2 25 | 36.3% | -31.1% | ||
| Q1 25 | 29.8% | -59.9% | ||
| Q4 24 | 9.1% | -53.8% | ||
| Q3 24 | 29.4% | -27.7% | ||
| Q2 24 | 22.6% | -42.9% | ||
| Q1 24 | 31.7% | -104.5% |
资本支出强度PRDOZLAB
| Q4 25 | 1.1% | 0.5% | ||
| Q3 25 | 0.9% | 2.6% | ||
| Q2 25 | 1.3% | 2.6% | ||
| Q1 25 | 0.8% | 1.5% | ||
| Q4 24 | 0.9% | 2.4% | ||
| Q3 24 | 0.6% | 1.3% | ||
| Q2 24 | 0.5% | 0.7% | ||
| Q1 24 | 0.7% | 1.1% |
现金转化率PRDOZLAB
| Q4 25 | — | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 1.92× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 1.00× | — | ||
| Q1 24 | 1.38× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRDO
| CTU | $107.0M | 51% |
| AIUS | $60.8M | 29% |
| University Of St Augustine For Health Sciences Llc | $43.7M | 21% |
| Other | $1.1M | 1% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
